Document Type
Article
Publication Date
2-26-2024
Abstract
Key Points:
- This study examines the impact of dupilumab on medication use for chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma patients.
- Patients on dupilumab had a reduction in oral/inhaled/topical steroids, antibiotics, and leukotriene receptor antagonists (LTRAs).
- The reduction in medication use had no impact on total polyp or SNOT-22 scores.
Recommended Citation
Garvey, Emily; Naimi, Bita; Duffy, Alexander; Kahn, Chase; Farquhar, Douglas; Rosen, Marc; Rabinowitz, Mindy; Pena Evertz, Damaris; Most, Jessica; Toskala, Elina; and Nyquist, Gurston G., "Medication Utilization for Patients With Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Asthma in 12 Months Pre- and Post-Dupilumab Initiation" (2024). Department of Otolaryngology - Head and Neck Surgery Faculty Papers. Paper 98.
https://jdc.jefferson.edu/otofp/98
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
PubMed ID
38409897
Language
English
Comments
This article is the author’s final published version in International Forum of Allergy & Rhinology, Volume 14, Issue 8, Aug 2024, Pages 1399-1401.
The published version is available at https://doi.org/10.1002/alr.23340. Copyright © 2024 The Authors. International Forum of Allergy & Rhinology published by Wiley Periodicals LLC on behalf of American Academy of Otolaryngic Allergy and American Rhinologic Society.
Publication made possible in part by support through a transformative agreement between Thomas Jefferson University and the publisher.